Article

Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus

The NHLBI's Framingham Heart Study, Framingham, Massachusetts, USA.
Circulation (Impact Factor: 14.95). 12/2005; 112(20):3066-72. DOI: 10.1161/CIRCULATIONAHA.105.539528
Source: PubMed

ABSTRACT The incidence of cardiovascular disease (CVD), coronary heart disease (CHD), and type 2 diabetes mellitus (T2DM) has not been well defined in persons with the metabolic syndrome (at least 3 of the following: abdominal adiposity, low HDL cholesterol, high triglycerides, hypertension, and impaired fasting glucose). The objective was to investigate risk for CVD, CHD, and T2DM according to metabolic syndrome traits.
The study followed a cohort of 3323 middle-aged adults for the development of new CVD, CHD, and T2DM over an 8-year period. In persons without CVD or T2DM at baseline, the prevalence of the metabolic syndrome (> or =3 of 5 traits) was 26.8% in men and 16.6% in women. There were 174 incident cases of CVD, 107 of CHD, and 178 of T2DM. In men, the metabolic syndrome age-adjusted relative risk (RR) and 95% CIs were RR=2.88 (95% CI 1.99 to 4.16) for CVD, RR=2.54 (95% CI 1.62 to 3.98) for CHD, and RR=6.92 (95% CI 4.47 to 10.81) for T2DM. Event rates and RRs were lower in women for CVD (RR=2.25, 95% CI 1.31 to 3.88) and CHD (RR=1.54, 95% CI 0.68 to 3.53), but they were similar for T2DM (RR=6.90, 95% CI 4.34 to 10.94). Population-attributable risk estimates associated with metabolic syndrome for CVD, CHD, and T2DM were 34%, 29%, and 62% in men and 16%, 8%, 47% in women.
Metabolic syndrome is common and is associated with an increased risk for CVD and T2DM in both sexes. The metabolic syndrome accounts for up to one third of CVD in men and approximately half of new T2DM over 8 years of follow-up.

0 Bookmarks
 · 
84 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Sarcopenic obesity (SO) in the elderly is associated with a loss of independence and the occurrence of metabolic complications. Despite this clinical importance, the associations of SO with various health outcomes in Asian elders are unclear. This study aimed to examine the association of SO with the prevalence of chronic illness and mobility limitations among 1204 subjects (576 men and 628 women) over the age of 60 from the Fifth Korea National Health and Nutrition Examination Survey (KNHANES V-1, 2010). The patients were placed in four categories based on body composition: normal, sarcopenic non-obese, normal obese, and SO. Data regarding functional dimensions were extracted from the EQ-5D in the KNHANES data (i.e., mobility, self-care, and usual activities). Pain/discomfort data were also extracted. The prevalence of SO was higher among the women than the men (7.2% vs. 4.1%). Hypertension and arthritis were associated with increased likelihoods of SO. People with SO were more likely to report problems in mobility (OR: 3.34, 95% CI, 1.97-5.65), self-care (men: OR: 2.92, 95% CI, 1.05-8.07, women: OR: 2.33, 95% CI, 1.29-4.21), and usual activity (men: OR: 2.28, 95% CI, 1.02-5.08, women: OR: 2.13, 95% CI, 1.29-3.52). In conclusion, our results showed that SO was associated with mobility, self-care, and usual activity problems. With the rapid ageing that is occurring in Korea, more attention should be given to the prevention and management of sarcopenic obese seniors.
    09/2014; 37. DOI:10.1016/j.pscr.2014.08.021
  • [Show abstract] [Hide abstract]
    ABSTRACT: Early detection of patients with elevated risk of developing diabetes mellitus is critical to the improved prevention and overall clinical management of these patients. We aim to apply association rule mining to electronic medical records (EMR) to discover sets of risk factors and their corresponding subpopulations that represent patients at particularly high risk of developing diabetes. Given the high dimensionality of EMRs, association rule mining generates a very large set of rules which we need to summarize for easy clinical use. We reviewed four association rule set summarization techniques and conducted a comparative evaluation to provide guidance regarding their applicability, strengths and weaknesses. We proposed extensions to incorporate risk of diabetes into the process of finding an optimal summary. We evaluated these modified techniques on a real-world prediabetic patient cohort. We found that all four methods produced summaries that described subpopulations at high risk of diabetes with each method having its clear strength. For our purpose, our extension to the Buttom-Up Summarization (BUS) algorithm produced the most suitable summary. The subpopulations identified by this summary covered most high-risk patients, had low overlap and were at very high risk of diabetes.
    IEEE Transactions on Knowledge and Data Engineering 01/2015; 27(1):130-141. DOI:10.1109/TKDE.2013.76 · 1.82 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To determine the durability over 96 weeks of safety and efficacy of lopinavir/ritonavir (LPV/r) and raltegravir (RAL) which was demonstrated to have non-inferior efficacy relative to a regimen of LPV/r with nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTIs) (Control) in primary analysis at 48 weeks. Open label, centrally randomised trial. Recruitment was from 37 primary and secondary care sites from Africa, Asia, Australia, Europe and Latin America. 541 HIV-1 infected adults virologically failing first-line non-NRTI + 2N(t)RTI, with no previous exposure to protease inhibitors or integrase strand transfer inhibitors were analysed, 425 completed 96 weeks follow up on randomised therapy. Randomisation was 1:1 to Control or RAL. Differences between the proportion of participants with plasma HIV-1 RNA (VL) <200 copies/mL by intention to treat were compared with a non-inferiority margin of -12%. Differences in biochemical, haematological and metabolic changes were assessed using T-tests. VL <200 copies/mL at 96 weeks was: RAL 80.4%, Control 76.0% (difference: 4.4 [95%CI -2.6, 11.3]) and met non-inferiority criteria. The RAL arm had a significantly higher mean change (difference Control-RAL; 95%CI) in haemoglobin (-2.9; -5.7, -1.1), total lymphocytes (-0.2; -0.3, -0.0), total cholesterol (-0.5; -0.8, -0.3), HDL cholesterol (-0.1; -0.1, -0.0) and LDL cholesterol (-0.3; -0.5, -0.2). At 96 weeks, both RAL and Control maintained efficacy greater than 75% and continued to demonstrate similar safety profiles. These results support the use of a combination LPV/r and RAL regimen as an option following failure of 1st line NNRTI + 2N(t)RTIs. ClinicalTrials.gov NCT00931463.
    PLoS ONE 10(2):e0118228. DOI:10.1371/journal.pone.0118228 · 3.53 Impact Factor